Rochester, NY, United States of America

Daniel Levy

USPTO Granted Patents = 59 

 

Average Co-Inventor Count = 4.7

ph-index = 5

Forward Citations = 101(Granted Patents)

Forward Citations (Not Self Cited) = 83(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Rochester, NY (US) (2008 - 2015)
  • Philadelphia, PA (US) (2010 - 2024)

Company Filing History:


Years Active: 2008-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
PI3K Inhibitors
JAK2 Inhibitors
Hydrophobic Carbon Nanotubes
Photoconductors
Organic Photosensitive Pigment
Electrophotographic Imaging
Imaging Device Components
Asymmetric Synthesis
Urea Resin
Intermediate Transfer Members
Benzothiazole Compounds
Thick Imaging Members
59 patents (USPTO):Explore Patents

Title: Daniel Levy: Pioneering Innovator in Pharmaceuticals

Introduction:

Daniel Levy, an accomplished inventor based in Rochester, NY, has made significant contributions to the pharmaceutical field with an impressive portfolio that includes 58 patents. His work primarily focuses on developing innovative solutions for cancer treatment through the discovery of PI3K inhibitors.

Latest Patents:

Among his latest patents, Daniel has developed crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor. This invention pertains to salts and crystalline forms of several compounds, which are noted for their potential efficacy in treating cancer and other diseases. These include 2-(3-(8-Amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, as well as variants like 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide. Another significant contribution includes the development of substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors, expanding the toolkit available for fighting complex diseases.

Career Highlights:

Throughout his career, Daniel has collaborated with renowned organizations such as Xerox Corporation and Incyte Corporation. His experience with these leading companies has further bolstered his expertise in drug development and innovation within the pharmaceutical sector.

Collaborations:

Daniel has worked closely with notable colleagues, including Jin Wu and Liang-Bih Lin. These collaborations have enriched his research efforts, leading to advancements that enhance the therapeutic options available for patients.

Conclusion:

With his remarkable achievements and dedication to pharmaceutical innovation, Daniel Levy continues to play a crucial role in advancing medical science. His inventions and collaborative spirit are setting new benchmarks in the quest for effective cancer treatments, demonstrating his commitment to improving lives through groundbreaking research and development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…